


Supplementary Fig. S4



Supplementary Fig. S4. **Therapeutic efficacy of the combination of α4-1BB and αCD40 with and without HPV peptide vaccine is CD8+ T cell dependent.** Mice were challenged subcutaneously with mEER cells (1×10^6) before being immunized intranasally at days 6 and 12, and receiving α4-1BB and αCD40 by the intraperitoneal route at days 6, 9 and 12. One group of mice was injected intraperitoneally with αCD8 antibody 1 day pre- and 1 day post-tumor challenge and every 3 days until mice were sacrificed. Tumor growth was monitored over time. Data are represented as means \pm SEM (n = 5 mice/group).